文献速递自身免疫性与大疱性皮肤病毛发、甲与色素性疾病

非节段型白癜风复发与再发的表型及自身免疫预测因素

Recurrence and relapse in nonsegmental vitiligo: phenotypic and autoimmune predictors from a large retrospective cohort.
PubMed 文献 · Br J Dermatol · 2026-01-01

基于长庚研究数据库2015—2024年的回顾性队列,纳入809例稳定≥6个月且随访≥1年的非节段型白癜风患者,266例(32.9%)出现复发/再发。肢端受累、甲状腺疾病及其他自身免疫共病为独立预测因素,肢端受累合并甲状腺疾病者风险约升高2.5倍。

要点

  • 肢端受累、甲状腺疾病及其他自身免疫共病是非节段型白癜风复发/再发的独立预测因素。
  • 肢端受累合并甲状腺疾病者复发/再发风险最高(aHR 2.44),应重点随访。
  • 可将表型与自身免疫风险因素纳入评估,支持风险分层的维持治疗与个体化监测。

核心结论

  • 肢端受累、甲状腺疾病及其他自身免疫共病是非节段型白癜风复发/再发的关键预测因素。
  • 肢端受累合并甲状腺疾病可识别出风险约升高2.5倍的高危亚组。
  • 将表型与自身免疫风险因素纳入临床评估,可能支持风险分层的维持治疗规划与个体化长期监测。

研究设计与样本

  • 回顾性队列研究,使用长庚研究数据库(2015—2024)。
  • 纳入稳定期≥6个月且有≥1年随访的非节段型白癜风患者,共809例。
  • 采用多变量Cox比例风险模型分析从稳定到首次复发/再发的时间,并预先校正年龄、性别、肢端与面部受累、基线体表面积分类(<5%、5-10%、>10%)、甲状腺疾病、其他自身免疫疾病、抗甲状腺过氧化物酶、抗核抗体水平及家族史。
  • 采用联合暴露模型评估肢端受累与甲状腺疾病的合并效应。

主要发现

  • 809例中266例(32.9%)出现复发/再发。
  • 肢端受累aHR 1.56(95%CI 1.20-2.03;P<0.001)。
  • 甲状腺疾病aHR 1.42(95%CI 1.07-1.89;P=0.015)。
  • 其他自身免疫共病aHR 1.73(95%CI 1.23-2.41;P=0.001)。
  • 肢端受累合并甲状腺疾病aHR 2.44(95%CI 1.64-3.59;P<0.001),单一因素效应较小或无统计学意义。

关键数值与推荐

  • 独立预测因素:肢端受累aHR 1.56(95%CI 1.20-2.03;P<0.001)。
  • 甲状腺疾病aHR 1.42(95%CI 1.07-1.89;P=0.015)。
  • 其他自身免疫共病aHR 1.73(95%CI 1.23-2.41;P=0.001)。
  • 联合暴露:肢端受累合并甲状腺疾病aHR 2.44(95%CI 1.64-3.59;P<0.001)。

临床怎么用

  • 对肢端受累、合并甲状腺疾病或其他自身免疫共病的非节段型白癜风患者,应加强定期随访。
  • 对高危患者可考虑维持治疗,并个体化制定长期监测方案。
  • 结合表型与自身免疫风险因素进行风险分层,有助于医患共同规划长期管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonsegmental vitiligo frequently recurs after treatment discontinuation despite successful repigmentation. Identifying patients at higher risk of recurrence/relapse is essential for guiding long-term management and maintenance strategies. OBJECTIVES: To identify phenotypic and autoimmune predictors of recurrence/relapse in nonsegmental vitiligo, and to establish a clinically relevant risk-stratification framework. METHODS: We conducted a retrospective cohort study using the Chang Gung Research Database (2015-2024). Patients with ≥ 6 months of documented clinical stability and ≥ 1 year of follow-up were included. Time from stability to first recurrence/relapse was analysed using multivariable Cox proportional hazards models adjusted a priori for age, sex, acral and facial involvement, baseline body surface area category (< 5%, 5-10%, > 10%), thyroid disease, other autoimmune diseases, anti-thyroid peroxidase, antinuclear antibody levels and family histories. A joint-exposure model assessed combined acral involvement and thyroid disease. RESULTS: Among 809 patients, 266 (32.9%) developed recurrence/relapse. Independent predictors included acral involvement [adjusted hazard ratio (aHR) 1.56, 95% confidence interval (CI) 1.20-2.03; P < 0.001], thyroid disease (aHR 1.42, 95% CI 1.07-1.89; P = 0.015) and other autoimmune comorbidities (aHR 1.73, 95% CI 1.23-2.41; P = 0.001). Joint-exposure analysis showed that patients with both acral involvement and thyroid disease had significantly elevated hazard (aHR 2.44, 95% CI 1.64-3.59; P < 0.001); whereas each factor alone conferred smaller or nonsignificant effects. CONCLUSIONS: Acral involvement, thyroid disease and other autoimmune comorbidities are key predictors of recurrence/relapse in nonsegmental vitiligo. Combined acral and thyroid involvement identifies a particularly high-risk subgroup with approximately 2.5-fold higher hazard. Incorporating these phenotypic and autoimmune risk factors into clinical assessment may support risk-stratified maintenance planning and more individualized long-term monitoring. Vitiligo is a chronic skin condition. It causes white patches when colour or pigment-producing cells (called ‘melanocytes’) are lost. In certain body areas vitiligo may become permanent (or ‘colour scarring’). This particularly affects the hands and feet. Vitiligo affects 0.5–2% of the population. Even after successful treatment and repigmentation, vitiligo can return. This often happens subtly and without any warning signs, such as inflammation or itching. Maintenance therapy may help to keep vitiligo stable. However, clear guidelines are lacking on who is at the highest risk, who benefits most or how long treatment should continue. In this study, we analysed data from 809 patients. These patients had non-segmental vitiligo (the most common type). They had remained stable for at least 6 months after treatment. Of these patients, 266 (32.9%) experienced recurrence/relapse. One of the strongest predictors of recurrence/relapse was vitiligo on the hands and feet. Other strong predictors included thyroid disease and other autoimmune conditions. Our findings highlight the importance of regular follow-up. They also show the potential benefit of maintenance therapy for people with vitiligo who are at higher risk. Understanding these risk factors can help patients and doctors plan long-term care. This can also reduce the likelihood of vitiligo returning.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Shih HY, Han-Wen L, Tsai TF, et al. Recurrence and relapse in nonsegmental vitiligo: phenotypic and autoimmune predictors from a large retrospective cohort. Br J Dermatol. 2026. PMID: 41451917. doi:10.1093/bjd/ljaf531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。